Work

High-Risk Myelodysplastic Syndrome (MDS): First Results of International Phase 2 Study with Oral Farnesyltransferase Inhibitor R115777 (ZARNESTRATM).

Year: 2004

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v104.11.68.68

Authors: Razelle Kurzrock, Pierre Fenaux, Azra Raza, Ghulam Mufti, Carlo Aul, Ulrich Germing, Rene Kerstens, Peter DePorre

Institutions: The University of Texas MD Anderson Cancer Center, King's College Hospital, Heinrich Heine University Düsseldorf

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2537438918

FWCI: 3.391

Cites:

Cited by: 19

Related to: 10